That comparison is interesting, but retinoids have their own large evidence base and regulatory categories that differ from copper peptide products
For context, semaglutide (Ozempic) went through Phase III trials involving thousands of patients across multiple countries before approval
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme
Rather than activating the growth hormone receptor, AOD 9604 functions as a pathway-specific modulator of lipid metabolism, enabling investigation of lipolysis and energy regulation in experimental systems without engagement of IGF-1mediated endocrine signaling
This peptide hormone regulates calcium homeostasis and bone metabolism, addressing the underlying pathophysiology of these bone disorders
working on medicinal chemistry of peptides - I strongly agree with Eric Topol, MD